Wells Fargo maintains Tandem Diabetes Care at Overweight, lowers price target to $25 from $27

Wells Fargo kept Tandem Diabetes Care's rating at Overweight but reduced its price target to $25 from $27, a 7.4% cut. This implies a 39.0% upside from the Nov 5 close of $17.99.

Original reporting
Published Nov 6, 2026, 2:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wells Fargo maintains Tandem Diabetes Care at Overweight, lowers price target to $25 from $27 — source image
Decision brief

The 30-second read

$TNDMBearishMed
01

Why it matters

Analyst target revisions often lead to short-term price moves, especially for small-cap biotech stocks.

02

Market read

A fresh downgrade can trigger sell pressure, offering a potential short opportunity for traders.

03

What to watch

Recent product launches or pipeline progress not reflected in the target.

Relevance 6/10Novelty 6/10Timing: today

Background

Wells Fargo's research team adjusted its outlook for Tandem Diabetes Care, reflecting new expectations for growth and profitability.

Company-level read

Ticker impact

$TNDMBearishHigh confidence
Context

Wells Fargo lowered its price target for Tandem Diabetes Care to $25 from $27, indicating a fresh analyst downgrade.

Expected impact

likely downward pressure as investors price in the lower target

Evidence & confidence

Analyst price target cuts are immediate signals that can trigger short-term sell-offs.

Market effects

May slightly dampen sentiment in the diabetes device sector.

Limited to U.S. biotech/medical device investors.

Minimal global impact.

Counterpoint

The target cut could be an overreaction; the stock may be undervalued relative to peers.

Key entities

  • Tandem Diabetes Care

    Medical device maker focused on insulin pumps.

  • Wells Fargo

    Provides equity research and price targets.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$TNDMMed

Why is Tandem Diabetes Care stock rallying today?

Tandem Diabetes Care (TNDM) stock rose 6.3% in pre-market trading after Stifel upgraded it to Buy with a $26 price target, citing an improving product pipeline and compelling valuation. The firm expects 50% upside and positive developments over the next year. TNDM recently received FDA clearance for its Tobi platform and reported strong Q3 2026 earnings, with revenue of $283.7 million, exceeding estimates. The stock trades below its 52-week high of $29.65.

$TNDMMedAI 8/10

Expanded Insulin Delivery Systems

Tandem Diabetes Care received Health Canada approval for its t:x2 insulin pump, expanding eligibility to adults with type 2 diabetes and pregnant individuals with type 1 diabetes. The pump is compatible with Abbott's FreeStyle Libre 3 Plus sensor, enabling minute-by-minute glucose readings. Clinical trials showed improved glucose management, including additional time in target range during pregnancy.